RXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty
Launched by UNIVERSITY OF PITTSBURGH · Dec 16, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The RXWell trial is studying how to help patients manage their mood and anxiety before and after knee surgery, specifically total knee arthroplasty (TKA). The goal is to see if using the RxWell platform can help improve recovery, reduce the need for pain medication like opioids, and enhance overall patient care. This study is currently active but not recruiting new participants.
To be eligible for this trial, participants need to be adults over 18 years old who are scheduled for elective knee surgery and have moderate levels of anxiety or depression as measured by specific questionnaires. However, individuals with severe mental health issues or those who cannot access a smartphone or tablet will not be able to participate. If you join the trial, you can expect to receive support for managing your mood during the surgery process, which may help you recover faster and use fewer resources. This approach aims to provide a more holistic way of taking care of patients’ emotional and physical health throughout their surgical journey.
Gender
ALL
Eligibility criteria
- Inclusion Criteria for the RXWell Study:
- • Adults \>18 years
- • Scheduled for elective primary total knee arthroplasty (TKA) or hip replacement (THA) at the approved UPMC hospitals
- • Moderately high levels of mood disorder symptoms on validated PROMIS measures, defined as a T-score \> or = to 60 on PROMIS Anxiety 4a short form and/or PROMIS Depression4a short form
- Exclusion Criteria for the RXWell Study:
- • Patients undergoing non-elective surgery or secondary arthroplasty
- • Active delirium, neurocognitive impairment, or severe intellectual disability
- • No access to a smart device (phone or tablet)
- • Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
- • Profound mood disorders requiring immediate intervention such as suicidal ideation, defined as a PROMIS Depression score of more than 70
- • A PROMIS Anxiety and/or Depression T-score \>70, which corresponds to severe anxiety and depression.
- • Patients needing immediate care will be referred to psychiatrists and primary team.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Monroeville, Pennsylvania, United States
Patients applied
Trial Officials
Ata Murat Kaynar, MD, MPH
Principal Investigator
UPMC Department of Anesthesiology and Perioperative Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials